Endoscopic placement of collagen at the lower esophageal sphincter to inhibit gastroesophageal reflux: A pilot study of 10 medically intractable patients

K. W. O'Connor, Glen Lehman

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Ten highly symptomatic and medically refractory refluxing patients were treated with a new endoscopic technique to decrease gastroesophageal reflux. Cross-linked bovine dermal collagen was injected beneath the mucosa in the area of the lower esophageal sphincter through a 23 gauge needle-tipped catheter. A mean volume of 85 ml of implant was injected in 0.5- to 4-ml increments over 3 to 10 injection sessions. All patients developed objective evidence of decreased reflux by one or more parameters. Nine out of 10 patients had decreased symptoms, and 8 of 9 patients had an increase in lower esophageal pressure after implant injection. Endoscopic implant treatment resulted in statistically significant improvement in symptom scores (p < 0.001), the standard acid reflux test (p = 0.009) and lower esophageal sphincter pressures (p = 0.002), but not in the endoscopic appearance of the esophagus (p = 0.131). Subjective and objective improvements in reflux parameters generally lasted 6 to 9 months with return toward pretreatment status by 12 months. Antibodies to bovine collagen developed in 5 of 10 subjects with no clinical sequelae and no apparent reactivity with human collagen. The technique is not difficult to perform and is well tolerated by patients, and the results indicate the potential for more general use with a more suitable implant material.

Original languageEnglish
Pages (from-to)106-112
Number of pages7
JournalGastrointestinal Endoscopy
Volume34
Issue number2
StatePublished - 1988

Fingerprint

Lower Esophageal Sphincter
Gastroesophageal Reflux
Collagen
Pressure
Injections
Esophagus
Needles
Mucous Membrane
Catheters
Skin
Acids
Antibodies

ASJC Scopus subject areas

  • Gastroenterology

Cite this

@article{09334de9f1ff4e53873e4b380f7d2fc4,
title = "Endoscopic placement of collagen at the lower esophageal sphincter to inhibit gastroesophageal reflux: A pilot study of 10 medically intractable patients",
abstract = "Ten highly symptomatic and medically refractory refluxing patients were treated with a new endoscopic technique to decrease gastroesophageal reflux. Cross-linked bovine dermal collagen was injected beneath the mucosa in the area of the lower esophageal sphincter through a 23 gauge needle-tipped catheter. A mean volume of 85 ml of implant was injected in 0.5- to 4-ml increments over 3 to 10 injection sessions. All patients developed objective evidence of decreased reflux by one or more parameters. Nine out of 10 patients had decreased symptoms, and 8 of 9 patients had an increase in lower esophageal pressure after implant injection. Endoscopic implant treatment resulted in statistically significant improvement in symptom scores (p < 0.001), the standard acid reflux test (p = 0.009) and lower esophageal sphincter pressures (p = 0.002), but not in the endoscopic appearance of the esophagus (p = 0.131). Subjective and objective improvements in reflux parameters generally lasted 6 to 9 months with return toward pretreatment status by 12 months. Antibodies to bovine collagen developed in 5 of 10 subjects with no clinical sequelae and no apparent reactivity with human collagen. The technique is not difficult to perform and is well tolerated by patients, and the results indicate the potential for more general use with a more suitable implant material.",
author = "O'Connor, {K. W.} and Glen Lehman",
year = "1988",
language = "English",
volume = "34",
pages = "106--112",
journal = "Gastrointestinal Endoscopy",
issn = "0016-5107",
publisher = "Mosby Inc.",
number = "2",

}

TY - JOUR

T1 - Endoscopic placement of collagen at the lower esophageal sphincter to inhibit gastroesophageal reflux

T2 - A pilot study of 10 medically intractable patients

AU - O'Connor, K. W.

AU - Lehman, Glen

PY - 1988

Y1 - 1988

N2 - Ten highly symptomatic and medically refractory refluxing patients were treated with a new endoscopic technique to decrease gastroesophageal reflux. Cross-linked bovine dermal collagen was injected beneath the mucosa in the area of the lower esophageal sphincter through a 23 gauge needle-tipped catheter. A mean volume of 85 ml of implant was injected in 0.5- to 4-ml increments over 3 to 10 injection sessions. All patients developed objective evidence of decreased reflux by one or more parameters. Nine out of 10 patients had decreased symptoms, and 8 of 9 patients had an increase in lower esophageal pressure after implant injection. Endoscopic implant treatment resulted in statistically significant improvement in symptom scores (p < 0.001), the standard acid reflux test (p = 0.009) and lower esophageal sphincter pressures (p = 0.002), but not in the endoscopic appearance of the esophagus (p = 0.131). Subjective and objective improvements in reflux parameters generally lasted 6 to 9 months with return toward pretreatment status by 12 months. Antibodies to bovine collagen developed in 5 of 10 subjects with no clinical sequelae and no apparent reactivity with human collagen. The technique is not difficult to perform and is well tolerated by patients, and the results indicate the potential for more general use with a more suitable implant material.

AB - Ten highly symptomatic and medically refractory refluxing patients were treated with a new endoscopic technique to decrease gastroesophageal reflux. Cross-linked bovine dermal collagen was injected beneath the mucosa in the area of the lower esophageal sphincter through a 23 gauge needle-tipped catheter. A mean volume of 85 ml of implant was injected in 0.5- to 4-ml increments over 3 to 10 injection sessions. All patients developed objective evidence of decreased reflux by one or more parameters. Nine out of 10 patients had decreased symptoms, and 8 of 9 patients had an increase in lower esophageal pressure after implant injection. Endoscopic implant treatment resulted in statistically significant improvement in symptom scores (p < 0.001), the standard acid reflux test (p = 0.009) and lower esophageal sphincter pressures (p = 0.002), but not in the endoscopic appearance of the esophagus (p = 0.131). Subjective and objective improvements in reflux parameters generally lasted 6 to 9 months with return toward pretreatment status by 12 months. Antibodies to bovine collagen developed in 5 of 10 subjects with no clinical sequelae and no apparent reactivity with human collagen. The technique is not difficult to perform and is well tolerated by patients, and the results indicate the potential for more general use with a more suitable implant material.

UR - http://www.scopus.com/inward/record.url?scp=0023926846&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023926846&partnerID=8YFLogxK

M3 - Article

C2 - 3366326

AN - SCOPUS:0023926846

VL - 34

SP - 106

EP - 112

JO - Gastrointestinal Endoscopy

JF - Gastrointestinal Endoscopy

SN - 0016-5107

IS - 2

ER -